Coherus Oncology (CHRS) Enterprise Value (2013 - 2026)
Coherus Oncology (CHRS) posted Enterprise Value of -$167.0 million for Q1 2026, up 2.95% sequentially from -$172.1 million in Q4 2025, and down 102.7% YoY from $6.2 billion in Q1 2025.
Coherus Oncology (CHRS) Enterprise Value (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Enterprise Value for 14 years, with the latest figure at -$167.0 million in Q1 2026.
- Quarterly Enterprise Value fell 102.7% year-over-year to -$167.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$167.0 million (down 102.7% YoY) and the FY2025 annual result came in at -$172.1 million, down 36.62% from the prior year.
- Enterprise Value improved to -$167.0 million in Q1 2026 per CHRS's latest filing, from -$172.1 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$82.4 million in Q1 2025 and troughed at -$325.7 million in Q1 2022.
- A 5-year average of -$182.1 million and a median of -$167.0 million in 2026 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value sank 102.81% in 2024, then jumped 68.28% in 2025.
- Over 5 years, Enterprise Value stood at -$191.7 million in 2022, then soared by 38.57% to -$117.7 million in 2023, then retreated by 7.0% to -$126.0 million in 2024, then sank by 36.62% to -$172.1 million in 2025, then climbed by 2.95% to -$167.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$167.0 million, -$172.1 million, and -$191.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | -105.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -105.31 Mn |
| Mar 31, 2026 | -167.05 Mn |
| Dec 31, 2025 | -172.13 Mn |
| Sep 30, 2025 | -191.66 Mn |
| Jun 30, 2025 | -237.64 Mn |
| Mar 31, 2025 | -82.41 Mn |
| Dec 31, 2024 | -125.99 Mn |
| Sep 30, 2024 | -97.69 Mn |
| Jun 30, 2024 | -159.24 Mn |
| Mar 31, 2024 | -259.78 Mn |
| Dec 31, 2023 | -117.75 Mn |
| Sep 30, 2023 | -131.08 Mn |
| Jun 30, 2023 | -144.71 Mn |
| Mar 31, 2023 | -128.09 Mn |
| Dec 31, 2022 | -191.68 Mn |
| Sep 30, 2022 | -286.81 Mn |
| Jun 30, 2022 | -275.48 Mn |
| Mar 31, 2022 | -325.68 Mn |
| Dec 31, 2021 | -417.20 Mn |
| Sep 30, 2021 | -468.71 Mn |